Pharmaceutical

AstraZeneca files patent for improved production of aav vectors using specific plasmid sequence

Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.

Mar 13, 2024 - 00:00
Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.
Read the original article

Tags:

Previous Article

Zealand Pharma files patent for pharmaceutical composition with GLP-1/GLP-2 dual...

Next Article

Dr. Reddy’s Laboratories files patent for 6-substituted pyridazine compounds for...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: KRAS, the ideal cancer drug target that became ‘undruggable,’ takes on a new glow

STAT+: KRAS, the ideal cancer drug target that became ‘...

Aug 31, 2023

Opinion: Where do we go from here on digital therapeutics?

Opinion: Where do we go from here on digital therapeutics?

Feb 1, 2024

STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs

STAT+: Biotech power broker John Maraganore offers advi...

Oct 18, 2023